Portola Pharmaceuticals Inc
What’s Portola’s Growth Strategy for Fiscal 2019?
The company expects to benefit from the Andexxa opportunity in the US and Europe until fiscal 2025.
How Is Portola’s Andexxa Placed in the First Quarter?
In its first quarter earnings conference call, Portola Pharmaceuticals (PTLA) highlighted the stocking of Andexxa by 300 hospitals in the US with a reorder rate of 55%.
FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019
Analysts expect Amicus Therapeutics’ revenues to rise YoY by 89.66% to $173.05 million in fiscal 2019.
What Are Analysts Recommending for FOLD and PTLA in May?
Amicus Therapeutics and Portola Pharmaceuticals both have a consensus “buy” rating in May.
Why Portola Pharmaceuticals Rose 8.09% on January 4
On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,
Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.
Recent Developments for Portola Pharmaceuticals
In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy.
A Look at Portola Pharmaceuticals’ Financial Performance
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018.
Opportunities and Competition for J&J’s Blockbuster Drug, Xarelto
Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF).
How Is Johnson & Johnson’s Xarelto Positioned after 3Q17?
In 3Q17, Johnson & Johnson’s (JNJ) Xarelto generated revenues of $635 million, a ~20% increase on a year-over-year (or YoY) basis and a 1% decline quarter-over-quarter.
Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial
On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.
A Key Overview of Portola
Portola Pharmaceuticals (PTLA) is a mid-cap stock with a market capitalization of ~$3 billion. It has a weight of 0.28% in the iShares Nasdaq Biotechnology ETF (IBB).
IBB Remained Flat Last Week
The iShares Nasdaq Biotechnology ETF (IBB) gained marginally by 0.57% in the week ending September 18, 2015.
Biogen: An Investor’s Overview to a Leading Biotech Company
One of the world’s leading biotechnology companies, Biogen specializes in manufacturing and marketing therapies to treat serious ailments related to the nervous system, immune system, and blood.